Berkeley Scott Share Discussion Threads

[sirrah] 16/12/2001 00:06

whoops
see previous

[sirrah] 16/12/2001 00:05

contin from 544

last posted turnover £100m
so solaraze would account for 34% of previous turnover
in reading skp bb skp seem to be debating
the milestone payment and royalty %
with launch first week 2002
so this may explain the 3rd one week bank extension
and why it should be the last
comments please

[mali7] 15/12/2001 23:50

Nice posts everyone, keep up the good work. Thanks.

[wetdream] 15/12/2001 18:34

Interesting article in The Times.
Looks like biotech takeovers may be flavour of the month?


Amgen set to launch $18bn bid for rival

BY NIC HOPKINS

TAKEOVER speculation returned to the drugs sector yesterday on reports that Amgen, the world’s biggest biotechnology group, was preparing an historic $18 billion (£12.4 billion) bid for the rival Immunex Corp.
The deal would be the largest of its kind in biotech history, and fuelled hopes of a wave of consolidation in the sector.

Analysts believe details of the deal, which is likely to include cash and shares, will be made available next week. “This will only hasten the consolidation that we are beginning to see across the pharmaceutical and biotech industries,” said one analyst. “There are plenty of companies out there just waiting to be snapped up.”

Both Amgen and Immunex develop a variety of prescription drugs. Home Products Corporation, the US group, owns 41 per cent of Immunex, which is reliant on its Enbrel medicine for rheumatoid arthritis. Amgen earns millions from Epogen, the anti-anaemia drug, and Neupogen, the immunity-booster.

The expected tie-up would see Amgen pay 15 per cent of the deal value, $2.7 billion, in cash and the rest in shares. The proposed merger would value Immunex at about $32 a share, or $18 billion.

Analysts and investors balked at the size of the deal, which represents a 30 per cent premium to Immunex’s closing price on Wednesday, sending shares of both firms lower. Amgen fell $3.20, or 5.32 per cent, to $57.01, while Immunex lost 75 cents, or 2.82 per cent, to $26.21.

The reaction among British drugmakers was mixed, with Celltech 11p firmer at 846p. The company has been the subject of much takeover speculation, with Biogen of the US and Switzerland’s Novartis seen as likely predators.

“When biotech companies start merging then minds begin to race,” a spokesman for Celltech said.

“It’s been said for many years that there are companies in the biotech sector that would benefit from consolidation, particularly in Europe.

“There’s a feeling that there are many small European firms ripe for the picking and several large US firms that have only a few products and need to diversify.”

[sirrah] 15/12/2001 14:40

apart from cusory mention in ft of bank extension no

[stand by] 15/12/2001 13:19

Is there anything in this weekends press?

[lovegod] 15/12/2001 11:55

Nice editorial. Once again thanks for the calming influence Mali7. Am in germany at the moment and even the ex-wife is thinking of buying, BL---- h--l.

[sirrah] 15/12/2001 11:49

nice one semorgan
so some maths
milestone payment $10m
15% of sales = 16-10 = $6m
bgp turnover after royalties on sales $34m
so bgp need to find $10 which is one aspect of meetings with bank now extended to 21st december

to be contin

[semorgan] 15/12/2001 10:36

As I Said, A Cruise in February for 'Her in doors' I think!

[semorgan] 15/12/2001 10:33

Broker upgrades and downgrades
By Sarah McMeekin

14 December 2001

SkyePharma

BUY at 57p suggests West LB Panmure. Solaraze received approval in the US in October last year, and this year SkyePharma secured Bioglan as a marketing partner. Bioglan's recent troubles led to questions concerning the future of Solaraze, but now Bioglan Pharma Inc has announced Solaraze will launch in January 2002, which West LB feels removes a lot of uncertainty surrounding Solaraze's future. The broker now predicts SkyePharma will receive the milestone payment of $10m and royalties at a rate of 15% of sales. West LB calculates this will amount to £16m, including the milestone payment, by December 2002, which will contribute to the broker's forecast of £7.7m maiden pre-tax profits at SkyePharma for that period.



Contact the editorial team at [e-mail]

Related broker research

Shaftesbury, Trinity Mirror, Aggreko, SMG, SkyePharma, Tesco

Broker upgrades and downgrades
By Sarah McMeekin

[linesal1] 15/12/2001 00:38

LOTS AND LOTS OF PROBABLES!!!
The facts are we do not know and will not know until it is announced.
the reason most people are not posting is because they have nothing worth saying that we do not already know. lets just be sensible about this and wait for the news, the mm selling 75000 doesnt bother me in fact i have toped up twice yesterday and today.
and when the news comes could someone please close the door after mad-trader and bolt it.
next post from me will not be until the news not that i am selling just waiting.

[bloakey] 15/12/2001 00:20

Sorry about the double posting.

[neelk0m0l] 15/12/2001 00:20

I think BGP should be able to raise some of the funding from the banks but they will also be forced to raise more funds from the shareholders by issuing more shares. But I can not see the offer being taken up unless it's heavily discounted.

Supposing there is an announcement of an Open Offer or a Rights Issue of something like 1 for 1 may be at 5p a share, which to me is looking every bit possible then the price of the existing shares will only drift down to the same price level as the new shares being offered. All you have to do is look at the recent examples, the most recent being Vocalis

[mad trader] 15/12/2001 00:09

thats because all the sane ones have cashed there chips

[sholcroft] 14/12/2001 20:54

I dont know about anyone else but I`m just about sick of these idiots making their stupid 7 day extensions annoucement. How about a little information on what they are discussing, Afterall, some of us do own part of the damn company. I know the longer the banks keeps giving extension the less likely the bank is to call it a day but its really boring me to death. Its like they are just playing games with people who bought shares. Please GOD.......some PROPER NEWS next week.............

[sirrah] 14/12/2001 19:20

i look forward to it mali7
and a good weekend to all

[mad trader] 14/12/2001 19:02

there is some good news next week this could rally to 20p giving people at least a fair chance..mali no offence yes i have bought this three times but that was when i thought they had a chance of funding all i can forsee is a heavily discounted rights issue.best of with marconi large gains on this stock next week.

[mali7] 14/12/2001 18:20

mad trader what's your problem this time???
I converted you once do I have to do it again???
I think you bought and sold out as you are a shorter! Anyway no one could stop someone from making profit, but BGP will survive. I remember you saying "BGP will be 5p soon" and after a week you said "BGP will be 50p soon". What is your style (ramping/deramping). Anyway enough time waisted on you.
Now back to BGP.
Again another extension, I am actually fed up of these extension I want some fresh hard news, I as a share holder want to know what's going on. I can understand they are in heavy talks about a rescue deal but after almost over two months I think we shareholder have every right to know what and who is involved in the deal at least. Everybody on this board I promise you I will get you some more news on Monday as I did once few months ago. Anyway have a nice weekend!

[iantc] 14/12/2001 16:49

the gamble is 50/50 better than the horses worth 2/3 grand of anybodys money

[mad trader] 14/12/2001 16:41

looks like you lot have one more week to get out or do the mm still have shares to offload ok there is hope ill admit that but why take such a huge gamble why not wait for good news then buy in?? what about a rights issue at 2p

[abbij] 14/12/2001 16:36

AFR) 14/12/01 16:32: Bioglan Pharma PLC - Bank Extention


Bioglan Pharma PLC - Bank Extention
RNS Number:7481O
Bioglan Pharma PLC
14 December 2001


For Immediate Release 14 December 2001



BIOGLAN PHARMA PLC

Extension of banking standstill to 21 December 2001



On 30 November 2001 Bioglan announced that its banks had agreed to extend the
standstill arrangements on its outstanding debt to 14 December 2001. The banks
today agreed to a further extension of these standstill arrangements to 21
December 2001. Although there can be no assurances that these financing
arrangements will be extended beyond 21 December 2001, Bioglan remains in
active discussion with its banks with a view to achieving a longer term
solution for the Company.



For further information, please contact:


Buchanan Communications

Tim Anderson : (m) 07710 328560 Switchboard : 020 7466 5000

Lisa Baderoon : (m) 07721 413496





Bioglan is a trademark of the Bioglan Group.


END

MSCDKQKBABDDCBD

MMMM
NNN

[abbij] 14/12/2001 16:34

u have no compassion, mad trader.i hope u sleep better tonight.

[bruce the goldfish] 14/12/2001 16:34

banks have extended the credit line by another week, its official.....the saga continues.....